Tyra Biosciences Reports $39.3 Million Net Loss and $412 Million in Total Assets for Q1 2026

Tyra Biosciences, Inc. reported a net loss of $39.3 million for the first quarter of 2026, an increase from a net loss of $28.1 million in the same period of the previous year. The company's total operating expenses rose to $42.0 million, up from $31.9 million in the first quarter of 2025, primarily driven by increased research and development costs associated with its clinical programs. Research and development expenses alone reached $33.5 million, compared to $25.0 million in the prior year, reflecting heightened activity in ongoing clinical trials for its lead product candidate, oral dabogratinib.

In terms of financial position, Tyra Biosciences reported total assets of $412.0 million as of March 31, 2026, a significant increase from $282.6 million at the end of 2025. This growth was largely attributed to a rise in cash and cash equivalents, which increased to $85.0 million from $77.4 million, and a substantial increase in marketable securities, which rose to $298.5 million from $178.6 million. The company’s stockholders’ equity also improved, reaching $387.6 million, up from $259.2 million at the end of the previous fiscal year.

Strategically, Tyra Biosciences has made notable advancements in its clinical pipeline, particularly with oral dabogratinib, which is currently being evaluated in three Phase 2 trials targeting various indications, including low-grade upper tract urothelial carcinoma and achondroplasia in children. The company has also expanded its employee headcount to support these initiatives, with personnel costs increasing significantly. As of March 31, 2026, the company had 12.9 million stock options outstanding, reflecting its ongoing commitment to incentivizing its workforce.

Operationally, Tyra Biosciences has seen a marked increase in its engagement metrics, with over 100 participants having received oral dabogratinib across multiple clinical studies. The company is also actively pursuing geographic expansion, with clinical trials being conducted at various sites both domestically and internationally. The company’s cash flow from financing activities was notably strong, with net proceeds of approximately $147.9 million from the sale of common stock under its at-the-market offering program, which has bolstered its liquidity position.

Looking ahead, Tyra Biosciences anticipates that its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operations into the second half of 2028. However, the company acknowledges the inherent uncertainties in clinical development and the potential need for additional capital to support its ongoing research and development efforts. The management remains focused on advancing its clinical programs and achieving regulatory approvals for its product candidates, which are critical for future revenue generation.